MTEP hydrochloride is primarily used in neuroscience research as a selective antagonist for the metabotropic glutamate receptor subtype 5 (mGluR5). It is widely applied in studies investigating the role of mGluR5 in various neurological and psychiatric disorders, such as anxiety, depression, schizophrenia, and Parkinson's disease. By blocking mGluR5, it helps researchers understand the receptor's involvement in synaptic plasticity, learning, and memory processes. Additionally, MTEP hydrochloride is utilized in preclinical studies to explore potential therapeutic targets for drug development aimed at modulating glutamate signaling pathways. Its high selectivity and potency make it a valuable tool for elucidating the complex mechanisms of glutamate neurotransmission in the central nervous system.